Find Clinical Trial

A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of 2g per day of strontium ranelate versus placebo on the bone quality and remodelling, as assessed on an alveolar bone biopsy extracted before dental implantation, in osteoporotic patients or in patients at risk of osteoporotic fracture.


← Back
Study Phase

Phase 2

Therapeutic Area

Rheumatology

Active substance/
Medical device

STRONTIUM RANELATE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS012911
Protocol CodeCL2-12911-039
EudraCT Code2011-002370-23


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility